Jaguar8 commented on a stock · Dec 2, 2024 20:02

NEWS

Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
Monday, 2nd December at 7:00 am
• Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints

• A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the control of 79% reduction in risk of death (HR 0.21, P = 0.04) with median OS improvement of 5.1 months and over 90% reduction in risk of progression or death (HR < 0.1, P = 0.003) with median PFS improvement of 2.9 months and improvement in the treatment arm over the control in ORR of 50% vs. 0%

• Phase 2b clinical study is planned in multiple selected indications, potentially targeting patients based on biomarkers

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more